Golimumab Is usually a human monoclonal antibody administered at the time per month by subcutaneous injection. While it's got an identical security and efficacy profile to other TNFi, golimumab is much less effective than other TNFi in individuals who have failed several biological treatments. Dealing with your health care provider https://www.directivepublications.org/journal-of-arthritis-and-rheumatology/